Stocks · News reference
Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.